UPDATE: Oppenheimer Raises PT of Sequenom to $10

According to a research report this morning, Oppenheimer raises PT to $10 on Sequenom

while management remains bullish as the MaterniT21 opportunity is under-appreciated. Oppenheimer stated, “While investors remain focused on the near term MaterniT21 ramp we see a number of positive catalysts on the horizon that could enhance long term value, including the signing of 2 major payor contracts and clarity on the FDA pathway. We are raising our 2012 and 2013 estimates to reflect the recent surge in testing volume.” Sequenom closed yesterday at $5.12 as Oppenheimer reiterates its Outperform rating.